123 related articles for article (PubMed ID: 23727044)
1. Discovery of non-LBD inhibitor for androgen receptor by structure-guide design.
Ryu BJ; Kim N; Kim JT; Koo TS; Yoo SE; Jeong SH; Kim SH; Kang NS
Bioorg Med Chem Lett; 2013 Jul; 23(13):3887-90. PubMed ID: 23727044
[TBL] [Abstract][Full Text] [Related]
2. Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.
Bradbury RH; Acton DG; Broadbent NL; Brooks AN; Carr GR; Hatter G; Hayter BR; Hill KJ; Howe NJ; Jones RD; Jude D; Lamont SG; Loddick SA; McFarland HL; Parveen Z; Rabow AA; Sharma-Singh G; Stratton NC; Thomason AG; Trueman D; Walker GE; Wells SL; Wilson J; Wood JM
Bioorg Med Chem Lett; 2013 Apr; 23(7):1945-8. PubMed ID: 23466225
[TBL] [Abstract][Full Text] [Related]
3. Multivalent peptidomimetic conjugates: a versatile platform for modulating androgen receptor activity.
Levine PM; Imberg K; Garabedian MJ; Kirshenbaum K
J Am Chem Soc; 2012 Apr; 134(16):6912-5. PubMed ID: 22509763
[TBL] [Abstract][Full Text] [Related]
4. 7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer.
Kandil S; Westwell AD; McGuigan C
Bioorg Med Chem Lett; 2016 Apr; 26(8):2000-4. PubMed ID: 26965862
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
Wu H; Ren J; Zhao L; Li Z; Ye W; Yang Y; Wang J; Bian J
Eur J Med Chem; 2021 May; 217():113376. PubMed ID: 33756125
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer.
Bradbury RH; Hales NJ; Rabow AA; Walker GE; Acton DG; Andrews DM; Ballard P; Brooks NA; Colclough N; Girdwood A; Hancox UJ; Jones O; Jude D; Loddick SA; Mortlock AA
Bioorg Med Chem Lett; 2011 Sep; 21(18):5442-5. PubMed ID: 21782422
[TBL] [Abstract][Full Text] [Related]
7. Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists.
Guo C; Pairish M; Linton A; Kephart S; Ornelas M; Nagata A; Burke B; Dong L; Engebretsen J; Fanjul AN
Bioorg Med Chem Lett; 2012 Apr; 22(7):2572-8. PubMed ID: 22377517
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of 4-benzyl-1-(2H)-phthalazinone derivatives as novel androgen receptor antagonists.
Inoue K; Urushibara K; Kanai M; Yura K; Fujii S; Ishigami-Yuasa M; Hashimoto Y; Mori S; Kawachi E; Matsumura M; Hirano T; Kagechika H; Tanatani A
Eur J Med Chem; 2015 Sep; 102():310-9. PubMed ID: 26295173
[TBL] [Abstract][Full Text] [Related]
9. In silico selection and cell-based characterization of selective and bioactive compounds for androgen-dependent prostate cancer cell.
Cruz EC; Carecho AR; Saidel ME; Montanari CA; Leitão A
Bioorg Med Chem Lett; 2017 Feb; 27(3):546-550. PubMed ID: 28011219
[TBL] [Abstract][Full Text] [Related]
10. Computationally identified novel diphenyl- and phenylpyridine androgen receptor antagonist structures.
Söderholm AA; Viiliäinen J; Lehtovuori PT; Eskelinen H; Roell D; Baniahmad A; Nyrönen TH
J Chem Inf Model; 2008 Sep; 48(9):1882-90. PubMed ID: 18712859
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3).
Ban F; Leblanc E; Li H; Munuganti RS; Frewin K; Rennie PS; Cherkasov A
J Med Chem; 2014 Aug; 57(15):6867-72. PubMed ID: 25025737
[TBL] [Abstract][Full Text] [Related]
12. 1,2,4-Oxadiazoles: a new class of anti-prostate cancer agents.
Khatik GL; Kaur J; Kumar V; Tikoo K; Nair VA
Bioorg Med Chem Lett; 2012 Mar; 22(5):1912-6. PubMed ID: 22326399
[TBL] [Abstract][Full Text] [Related]
13. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
Quéro L; Giocanti N; Hennequin C; Favaudon V
Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
[TBL] [Abstract][Full Text] [Related]
14. 20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth.
Fousteris MA; Schubert U; Roell D; Roediger J; Bailis N; Nikolaropoulos SS; Baniahmad A; Giannis A
Bioorg Med Chem; 2010 Oct; 18(19):6960-9. PubMed ID: 20826091
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer.
Guo C; Kephart S; Ornelas M; Gonzalez J; Linton A; Pairish M; Nagata A; Greasley S; Elleraas J; Hosea N; Engebretsen J; Fanjul AN
Bioorg Med Chem Lett; 2012 Jan; 22(2):1230-6. PubMed ID: 22197140
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and anticancer activities of new 3-allylthio-6-(mono or disubstituted)aminopyridazines.
Won YH; Park MS
Arch Pharm Res; 2010 Feb; 33(2):189-96. PubMed ID: 20195817
[TBL] [Abstract][Full Text] [Related]
17. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
[TBL] [Abstract][Full Text] [Related]
18. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationship of novel (benzoylaminophenoxy)phenol derivatives as anti-prostate cancer agents.
Kazui Y; Fujii S; Yamada A; Ishigami-Yuasa M; Kagechika H; Tanatani A
Bioorg Med Chem; 2018 Oct; 26(18):5118-5127. PubMed ID: 30228001
[TBL] [Abstract][Full Text] [Related]
20. "True" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancer.
Caboni L; Kinsella GK; Blanco F; Fayne D; Jagoe WN; Carr M; Williams DC; Meegan MJ; Lloyd DG
J Med Chem; 2012 Feb; 55(4):1635-44. PubMed ID: 22280402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
